Trials / Withdrawn
WithdrawnNCT00620607
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
Conditions
- Stomach Neoplasms
- Metastatic or Locally Advanced Gastric Cancer
- Metastatic or Local Advanced GE Junction Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | huC242-DM4 | dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2010-05-01
- Completion
- 2010-09-01
- First posted
- 2008-02-21
- Last updated
- 2015-08-26
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00620607. Inclusion in this directory is not an endorsement.